Skip to main content
. 2023 May 26;5(3):e220180. doi: 10.1148/rycan.220180

Figure 3:

Simultaneous detection of the trastuzumab (TRA)-Aurelia-1 and Aurelia-2 gold nanorod (GNR) on images of athymic mice (n = 5; survival rate of 100%) bearing an orthotopically implanted mammary fat pad tumor (DY36T2Q or MDA‐MB‐231) at the predetermined time point of 6 hours after the intravenous injection of TRA-Aurelia-1 GNR, TRA-Aurelia-2 GNR, or in combination. (A, B) DY36T2Q breast tumor–bearing mice had high TRA-Aurelia-1 (blue color bar; 14.8-fold increase, P < .0001) and TRA-Aurelia-2 (red color bar; 20.8-fold increase, P < .0001) GNR uptake in the tumor in comparison with MDA-MB-231 tumor–bearing mice. (C, D) Bar graphs of multispectral optoacoustic tomography (MSOT) signal uptake in each cell line demonstrate that MDA‐MB‐231 breast tumor–bearing mice had negligible amounts of both TRA-Aurelia-1 and TRA-Aurelia-2 GNRs. *** = P < .001, a.u. = arbitrary units, HER2+ = human epidermal growth factor receptor 2–positive cells, HER2- = human epidermal growth factor receptor 2–negative cells.

Simultaneous detection of the trastuzumab (TRA)-Aurelia-1 and Aurelia-2 gold nanorod (GNR) on images of athymic mice (n = 5; survival rate of 100%) bearing an orthotopically implanted mammary fat pad tumor (DY36T2Q or MDA‐MB‐231) at the predetermined time point of 6 hours after the intravenous injection of TRA-Aurelia-1 GNR, TRA-Aurelia-2 GNR, or in combination. (A, B) DY36T2Q breast tumor–bearing mice had high TRA-Aurelia-1 (blue color bar; 14.8-fold increase, P < .0001) and TRA-Aurelia-2 (red color bar; 20.8-fold increase, P < .0001) GNR uptake in the tumor in comparison with MDA-MB-231 tumor–bearing mice. (C, D) Bar graphs of multispectral optoacoustic tomography (MSOT) signal uptake in each cell line demonstrate that MDA‐MB‐231 breast tumor–bearing mice had negligible amounts of both TRA-Aurelia-1 and TRA-Aurelia-2 GNRs. *** = P < .001, a.u. = arbitrary units, HER2+ = human epidermal growth factor receptor 2–positive cells, HER2- = human epidermal growth factor receptor 2–negative cells.